IGLV1-51: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: IGLV1-51

NCBI ID: G28820

IGLV1-51

Other Name(s): V1-19 | IGLV151 | Immunoglobulin lambda variable 1-51 | immunoglobulin lambda variable 1-51

IGLV1-51: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

IGLV1-51 (V1-19) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the Integrin伪6 subfamily of the immunoglobulin superfamily and is involved in the development and maintenance of tissues and organs.

IGLV1-51 has been identified as a potential drug target (or biomarker) due to its unique structure and its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key features of IGLV1-51 is its ability to interact with several different cell surface molecules, including cadherins, integrins, and adhesion molecules. This interaction allows IGLV1-51 to play a role in the development and maintenance of tissues and organs, as well as in the regulation of cellular processes such as cell growth, migration, and adhesion.

IGLV1-51 has been shown to be involved in several diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that IGLV1-51 is overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. This overexpression is thought to contribute to the development and progression of these diseases.

In addition to its involvement in cancer, IGLV1-51 has also been shown to be involved in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have shown that IGLV1-51 is expressed in the brains of individuals with these conditions and that it is involved in the development and progression of these diseases.

IGLV1-51 has also been shown to be involved in autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. Studies have shown that IGLV1-51 is expressed in the tissues of individuals with these conditions and that it is involved in the development and progression of these diseases.

In conclusion, IGLV1-51 is a protein that is involved in the development and maintenance of tissues and organs, as well as in the regulation of cellular processes. Its unique structure and its ability to interact with several different cell surface molecules make it a potential drug target (or biomarker) for a variety of diseases. Further research is needed to fully understand the role of IGLV1-51 in these diseases and to develop effective treatments.

Protein Name: Immunoglobulin Lambda Variable 1-51

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268)

The "IGLV1-51 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLV1-51 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets